Alnylam announces u.s. fda has granted priority review of lumasiran new drug application for treatment of primary hyperoxaluria type 1

Alnylam announces u.s. food and drug administration has granted priority review of the lumasiran new drug application for the treatment of primary hyperoxaluria type 1.alnylam pharmaceuticals - pdufa date set for dec 3, 2020.alnylam pharmaceuticals - fda indicated not planning advisory committee meeting as part of lumasiran nda review.alnylam pharmaceuticals - marketing authorisation application for lumasiran submitted to, validated by ema.alnylam pharmaceuticals - fda also granted priority review for lumasiran nda.
ALNY Ratings Summary
ALNY Quant Ranking